Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

3,4-Methylenedioxymethamphetamine, mephedrone, and β-phenylethylamine release dopamine from the cytoplasm by means of transporters and keep the concentration high and constant by blocking reuptake.

Zsilla G, Hegyi DE, Baranyi M, Vizi ES.

Eur J Pharmacol. 2018 Oct 15;837:72-80. doi: 10.1016/j.ejphar.2018.08.037. Epub 2018 Aug 30.

PMID:
30172789
2.

Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms.

Harsing LG Jr, Timar J, Szabo G, Udvari S, Nagy KM, Marko B, Zsilla G, Czompa A, Tapolcsanyi P, Kocsis A, Matyus P.

Curr Pharm Des. 2015;21(17):2291-303.

PMID:
25578890
3.

Neurochemical Changes in the Mouse Hippocampus Underlying the Antidepressant Effect of Genetic Deletion of P2X7 Receptors.

Csölle C, Baranyi M, Zsilla G, Kittel A, Gölöncsér F, Illes P, Papp E, Vizi ES, Sperlágh B.

PLoS One. 2013 Jun 21;8(6):e66547. doi: 10.1371/journal.pone.0066547. Print 2013.

4.

Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules - glycine transporter type 1 and its inhibitors (review).

Harsing LG, Zsilla G, Matyus P, Nagy KM, Marko B, Gyarmati Z, Timar J.

Acta Physiol Hung. 2012 Mar;99(1):1-17. doi: 10.1556/APhysiol.99.2012.1.1. Review.

PMID:
22425803
5.

Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

Nagy K, Marko B, Zsilla G, Matyus P, Pallagi K, Szabo G, Juranyi Z, Barkoczy J, Levay G, Harsing LG Jr.

Neurochem Res. 2010 Dec;35(12):2096-106. doi: 10.1007/s11064-010-0241-0. Epub 2010 Aug 20.

PMID:
20725779
6.

Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus.

Sperlágh B, Zsilla G, Baranyi M, Illes P, Vizi ES.

Neuroscience. 2007 Oct 12;149(1):99-111. Epub 2007 Aug 1.

PMID:
17850981
7.

Carrier-mediated release of monoamines induced by the nicotinic acetylcholine receptor agonist DMPP.

Szász BK, Mayer A, Zsilla G, Lendvai B, Vizi ES, Kiss JP.

Neuropharmacology. 2005 Sep;49(3):400-9.

PMID:
15993437
9.
10.

Azaberbene derivatives as alpha 2A-adrenoceptor antagonists.

Szántay C, Szabó L, Zsilla G, Vizi SE.

Arch Pharm (Weinheim). 2002 Jan;335(1):22-6.

PMID:
11933676
11.

Halothane decreases impulse-dependent but not cytoplasmic release of dopamine from rat striatal slices.

Adachi YU, Watanabe K, Higuchi H, Satoh T, Zsilla G.

Brain Res Bull. 2001 Dec;56(6):521-4.

PMID:
11786236
12.

Halothane enhances acetylcholine release by decreasing dopaminergic activity in rat striatal slices.

Adachi YU, Watanabe K, Higuchi H, Satoh T, Zsilla G.

Neurochem Int. 2002 Mar;40(3):189-93.

PMID:
11741001
13.

The nootropic drug vinpocetine inhibits veratridine-induced [Ca2+]i increase in rat hippocampal CA1 pyramidal cells.

Zelles T, Franklin L, Koncz I, Lendvai B, Zsilla G.

Neurochem Res. 2001 Sep;26(8-9):1095-100.

PMID:
11699936
14.
15.

Multiple cellular mechanisms mediate the effect of lobeline on the release of norepinephrine.

Sántha E, Sperlágh B, Zelles T, Zsilla G, Tóth PT, Lendvai B, Baranyi M, Vizi ES.

J Pharmacol Exp Ther. 2000 Jul;294(1):302-7.

PMID:
10871326
16.

A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum.

Kiss JP, Hennings EC, Zsilla G, Vizi ES.

Neurochem Int. 1999 Apr;34(4):345-50.

PMID:
10372921
17.

Isoproterenol inhibits Il-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages.

Haskó G, Németh ZH, Szabó C, Zsilla G, Salzman AL, Vizi ES.

Brain Res Bull. 1998;45(2):183-7.

PMID:
9443838
18.

Age-dependent changes of presynaptic neuromodulation via A1-adenosine receptors in rat hippocampal slices.

Sperlágh B, Zsilla G, Baranyi M, Kékes-Szabó A, Vizi ES.

Int J Dev Neurosci. 1997 Oct;15(6):739-47.

PMID:
9402224
19.

Subtype-specificity of the presynaptic alpha 2-adrenoceptors modulating hippocampal norepinephrine release in rat.

Kiss JP, Zsilla G, Mike A, Zelles T, Toth E, Lajtha A, Vizi ES.

Brain Res. 1995 Mar 20;674(2):238-44.

PMID:
7796102
20.

Differential changes in presynaptic modulation of transmitter release during aging.

Zsilla G, Zelles T, Mike A, Kékes-Szabó A, Milusheva E, Vizi ES.

Int J Dev Neurosci. 1994 Apr;12(2):107-15.

PMID:
7942086
21.

The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.

Zsilla G, Földi P, Held G, Székely AM, Knoll J.

Pol J Pharmacol Pharm. 1986 Jan-Feb;38(1):57-67.

PMID:
3020531
22.

(-)-Deprenyl a selective MAO "B' inhibitor, increases [3H]imipramine binding and decreases beta-adrenergic receptor function.

Zsilla G, Barbaccia ML, Gandolfi O, Knoll J, Costa E.

Eur J Pharmacol. 1983 Apr 22;89(1-2):111-7.

PMID:
6305680
23.

The action of (-) deprenyl on monoamine turnover rate in rat brain.

Zsilla G, Knoll J.

Adv Biochem Psychopharmacol. 1982;31:211-7. No abstract available.

PMID:
6805258
24.

The action of single and repeated doses of p-bromo-methamphetamine on the monoamine content and turnover rate in rat brain.

Zsilla G, Knoll B, Knoll J.

Neuropharmacology. 1981 Sep;20(9):833-8. No abstract available.

PMID:
6170025
25.

Evidence of the modulatory role of serotonin in acetylcholine release from striatal interneurons.

Vizi ES, Hársing LG Jr, Zsilla G.

Brain Res. 1981 May 11;212(1):89-99.

PMID:
7225867
26.

Constant rate infusion of deuterated phosphorylcholine to measure the effects of morphine on acetylcholine turnover rate in specific nuclei of rat brain.

Zsilla G, Racagni G, Cheney DL, Costa E.

Neuropharmacology. 1977 Jan;16(1):25-30. No abstract available.

PMID:
834360
27.
29.

The measurement of acetylcholine turnover rate in brain structures.

Racagni G, Cheney DL, Zsilla G, Costa E.

Neuropharmacology. 1976 Dec;15(12):723-36. Review. No abstract available.

PMID:
796753
30.

Regional changes in the rate of turnover of acetylcholine in rat brain following diazepam or muscimol.

Zsilla G, Cheney DL, Costa E.

Naunyn Schmiedebergs Arch Pharmacol. 1976 Sep;294(3):251-5.

PMID:
1004636
31.

Accumulation of cGMP in striatum of rats injected with narcotic analgesics: antagonism by naltrexone.

Racagni G, Zsilla G, Guidotti A, Costa E.

J Pharm Pharmacol. 1976 Mar;28(3):258-60. No abstract available.

PMID:
6708
32.

Differences in the action of various drugs on striatal acetylcholine and choline content in rats killed by decapitation of microwave radiation.

Cheney DL, Racagni G, Zsilla G, Costa E.

J Pharm Pharmacol. 1976 Jan;28(1):75-7. No abstract available.

PMID:
6659
33.

The metabolism of azidomorphine in the rat.

Knoll J, Zsilla G, Makleit S.

Med Biol. 1975 Dec;53(6):501-4.

PMID:
1214542
34.

Turnover rate of tyrosine hydroxylase during Trans-synaptic induction.

Chuang D, Zsilla G, Costa E.

Mol Pharmacol. 1975 Nov;11(6):784-94. No abstract available.

PMID:
1666
35.

An analysis at synaptic level of the morphine action in striatum and N. accumbens: dopamine and acetylcholine interactions.

Costa E, Cheney DL, Racagni G, Zsilla G.

Life Sci. 1975 Jul 1;17(1):1-8. No abstract available.

PMID:
167253
36.

Possible mechanism of the low tolerance capacity of azidomorphine and azidocodeine.

Knoll J, Zsilla G.

Biochem Pharmacol. 1974 Feb 1;23(3):745-50. No abstract available.

PMID:
4822754

Supplemental Content

Loading ...
Support Center